SIC
FATE icon

SJS Investment Consulting’s Fate Therapeutics FATE Stock Holding History

SJS Investment Consulting’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95K Buy
721
+656
+1,009% +$1.21K ﹤0.01% 1788
2026
Q1 		$78 Buy
+65
New +$79 ﹤0.01% 2176

Other funds holding FATE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
NCM
Narwhal Capital Management Marietta, Georgia $1.45B AUM 28.39% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

SJS Investment Consulting's FATE Position: Q2 2026 in Review

SJS Investment Consulting increased its Fate Therapeutics (FATE) stake by 1,009% in Q2 2026, buying an estimated $1.21K and bringing the position to 721 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1788.

SJS Investment Consulting first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • SJS Investment Consulting held 721 shares of Fate Therapeutics worth $1.95K as of Q2 2026.
  • SJS Investment Consulting bought 656 Fate Therapeutics shares in Q2 2026, an estimated $1.21K.
  • Fate Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1788 holding.
  • SJS Investment Consulting first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.